When added to vaccines, adjuvants such as aluminum salts can provide various benefits to drug products.
Understanding the challenges associated with the development and manufacture of vaccines that include aluminum salts is essential so that a newly formed partnership with a CDMO leads to successful vaccine manufacturing.
Aluminum adjuvants such as aluminum phosphate, aluminum hydroxide, aluminum potassium sulfate, and amorphous aluminum hydroxyphosphate sulfate (known as aluminum salts, or alum) are added to many newer-generation vaccines based on their ability to improve the overall potency of a vaccine. They can increase immunogenicity of vaccine antigens and enhance the overall immune response against the antigen and have demonstrated efficacy with less frequent administration when added to a vaccine.1-3
Partnering with a CDMO with experience in the development and manufacture of next-generation vaccines can help streamline processes and ensure success. Jackie Fan, MSc (ENG), PEng, Manager of Manufacturing Science & Technology at Resilience highlights Resilience’s approach to supporting vaccine discovery and development using aluminum adjuvants.
WHAT YOU'LL LEARN
- ● Detailed information on the challenges involving filterability, adjuvant supplier containers, and the handling of gel suspensions
- ● How you can overcome these challenges to support vaccine development
- ● How Resilience collaborates with industry partners to expedite next-generation vaccine manufacturing for live viruses, viral vectors, oncolytic viruses and vectors, potency assays, virus-like particles, and antigen vaccines
